Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 1/20 | 0.35 |
| ▸ | FTO | Q9C0B1 | 1/20 | 0.33 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.33 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.32 |
| ▸ | RORC | P51449 | 2/20 | 0.32 |
| ▸ | PFKFB3 | Q16875 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 2/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
| ▸ | SYK | P43405 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20674252 | 0.82 | PIK3CB (0.34) | CYP2A6RORCKDM4ETRPM8 | |
| SCHEMBL20674060 | 0.82 | — | — | |
| SCHEMBL20674087 | 0.78 | CCR4 (0.34) | FTO | |
| SCHEMBL23937755 | 0.77 | FTO (0.36) | PKMFTOPFKFB3TSHRLMNA | |
| SCHEMBL20674256 | 0.77 | TSHR (0.32) | TSHR | |
| SCHEMBL23937759 | 0.74 | TSHR (0.43) | PKMFTOSIRT6RORCTSHR | |
| SCHEMBL23937850 | 0.72 | BAZ2B (0.40) | PKMTSHRKDM4ELMNA | |
| SCHEMBL23937743 | 0.72 | FTO (0.34) | FTOLMNA | |
| SCHEMBL21440750 | 0.70 | — | — | |
| SCHEMBL20674250 | 0.69 | LCK (0.38) | KDM4ELMNASYK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3399968-B1 | SELECTIVE INHIBITORS OF CLINICALLY IMPORTANT MUTANTS OF THE EGFR TYROSINE KINASE | CS PHARMATECH LTD (KY) | 2021-10-20 | — | — | EP | disclosed |